Develops treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's, aiming to improve cognitive function.
Annovis Bio, Inc. is a clinical stage biopharmaceutical company specializing in the development of innovative treatments for neurodegenerative diseases. Founded in 2008 and headquartered in Berwyn, Pennsylvania, Annovis Bio focuses on advancing a promising drug platform aimed at combating conditions such as Alzheimer's disease (AD), Parkinson's disease, and related neurodegenerative disorders. At the forefront of their pipeline is ANVS401, currently undergoing Phase 2a clinical trials. This compound shows potential for addressing not only AD but also Parkinson's disease and Alzheimer's disease in Down Syndrome.
In addition to ANVS401, Annovis Bio is actively developing ANVS405, a compound designed to protect brain function following traumatic brain injury and stroke. Furthermore, the company is advancing ANVS301 through Phase I clinical trials, with the goal of enhancing cognitive abilities in the later stages of AD and dementia. This comprehensive approach underscores Annovis Bio's commitment to tackling various facets of neurodegeneration, leveraging their research to potentially improve outcomes for patients facing these debilitating conditions.
With a robust pipeline and a dedicated team of researchers and clinicians, Annovis Bio remains focused on advancing therapies that not only target the underlying causes of neurodegeneration but also aim to improve the quality of life for individuals affected by these challenging diseases. Through ongoing clinical trials and strategic development efforts, the company continues to position itself at the forefront of neurodegenerative research, striving to deliver meaningful advancements in treatment options for patients worldwide.